Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 286

1.

Masked Uncontrolled Hypertension Is Not Attributable to Medication Nonadherence.

Siddiqui M, Judd EK, Dudenbostel T, Zhang B, Gupta P, Tomaszewski M, Patel P, Oparil S, Calhoun DA.

Hypertension. 2019 Sep;74(3):652-659. doi: 10.1161/HYPERTENSIONAHA.119.13258. Epub 2019 Jul 22.

PMID:
31327263
2.

Resistant Hypertension Management: Comparison of the 2017 American and 2018 European High Blood Pressure Guidelines.

Grassi G, Calhoun DA, Mancia G, Carey RM.

Curr Hypertens Rep. 2019 Jul 18;21(9):67. doi: 10.1007/s11906-019-0974-3. Review.

PMID:
31321564
3.

Prevalence of refractory hypertension in the United States from 1999 to 2014.

Buhnerkempe MG, Botchway A, Prakash V, Al-Akchar M, Nolasco Morales CE, Calhoun DA, Flack JM.

J Hypertens. 2019 Sep;37(9):1797-1804. doi: 10.1097/HJH.0000000000002103.

PMID:
31058798
4.

The Year in Clinical Hypertension From Other Pages.

Calhoun DA.

Am J Hypertens. 2019 Apr 22;32(5):441-444. doi: 10.1093/ajh/hpz021. No abstract available.

PMID:
31009040
5.

Treatment of Resistant and Refractory Hypertension.

Acelajado MC, Hughes ZH, Oparil S, Calhoun DA.

Circ Res. 2019 Mar 29;124(7):1061-1070. doi: 10.1161/CIRCRESAHA.118.312156.

PMID:
30920924
6.

Plasma xanthine oxidase activity is related to increased sodium and left ventricular hypertrophy in resistant hypertension.

Butts B, Calhoun DA, Denney TS Jr, Lloyd SG, Gupta H, Gaddam KK, Aban I, Oparil S, Sanders PW, Patel R, Collawn JF, Dell'Italia LJ.

Free Radic Biol Med. 2019 Apr;134:343-349. doi: 10.1016/j.freeradbiomed.2019.01.029. Epub 2019 Jan 26.

PMID:
30695690
7.

Association Between Sleep Apnea and Blood Pressure Control Among Blacks.

Johnson DA, Thomas SJ, Abdalla M, Guo N, Yano Y, Rueschman M, Tanner RM, Mittleman MA, Calhoun DA, Wilson JG, Muntner P, Redline S.

Circulation. 2019 Mar 5;139(10):1275-1284. doi: 10.1161/CIRCULATIONAHA.118.036675.

PMID:
30586763
8.

Prevalence of Apparent Treatment-Resistant Hypertension in the United States.

Carey RM, Sakhuja S, Calhoun DA, Whelton PK, Muntner P.

Hypertension. 2019 Feb;73(2):424-431. doi: 10.1161/HYPERTENSIONAHA.118.12191.

PMID:
30580690
9.

Out-of-Clinic Sympathetic Activity Is Increased in Patients With Masked Uncontrolled Hypertension.

Siddiqui M, Judd EK, Jaeger BC, Bhatt H, Dudenbostel T, Zhang B, Edwards LJ, Oparil S, Calhoun DA.

Hypertension. 2019 Jan;73(1):132-141. doi: 10.1161/HYPERTENSIONAHA.118.11818.

PMID:
30571547
10.

Web Exclusive. Annals On Call - Primary Aldosteronism: How Often Are We Missing It?

Centor RM, Calhoun DA.

Ann Intern Med. 2018 Nov 20;169(10):OC1. doi: 10.7326/A18-0008. No abstract available.

PMID:
30452580
11.

Resistant Hypertension: An Update.

Calhoun DA, Schiffrin EL, Flack JM.

Am J Hypertens. 2019 Jan 1;32(1):1-3. doi: 10.1093/ajh/hpy156. No abstract available.

PMID:
30407514
12.

Blood Pressure Measurement Challenges in Severely Obese Patients.

Siddiqui M, Calhoun DA.

Am J Hypertens. 2019 Jan 15;32(2):139-140. doi: 10.1093/ajh/hpy162. No abstract available.

PMID:
30383208
13.

Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, Egan BM, Flack JM, Gidding SS, Judd E, Lackland DT, Laffer CL, Newton-Cheh C, Smith SM, Taler SJ, Textor SC, Turan TN, White WB; American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council.

Hypertension. 2018 Nov;72(5):e53-e90. doi: 10.1161/HYP.0000000000000084.

14.

Advances in resistant hypertension.

Calhoun DA.

Ann Transl Med. 2018 Aug;6(15):294. doi: 10.21037/atm.2018.07.21. No abstract available.

15.

Optimal Systolic Blood Pressure Target in Resistant and Non-Resistant Hypertension: A Pooled Analysis of Patient-Level Data from SPRINT and ACCORD.

Smith SM, Gurka MJ, Calhoun DA, Gong Y, Pepine CJ, Cooper-DeHoff RM.

Am J Med. 2018 Dec;131(12):1463-1472.e7. doi: 10.1016/j.amjmed.2018.08.005. Epub 2018 Aug 22.

PMID:
30142317
16.

Refractory Hypertension Is not Attributable to Intravascular Fluid Retention as Determined by Intracardiac Volumes.

Velasco A, Siddiqui M, Kreps E, Kolakalapudi P, Dudenbostel T, Arora G, Judd EK, Prabhu SD, Lloyd SG, Oparil S, Calhoun DA.

Hypertension. 2018 Aug;72(2):343-349. doi: 10.1161/HYPERTENSIONAHA.118.10965. Epub 2018 Jun 4.

17.

Case of Refractory Hypertension Controlled After Aortic and Mitral Valve Replacement and Coronary Artery Bypass Grafting.

Siddiqui M, Phillips RA, Bursztyn M, Sica D, Velasco A, Judd EK, Dudenbostel T, Lloyd SG, Oparil S, Calhoun DA.

Hypertension. 2018 Jul;72(1):3-9. doi: 10.1161/HYPERTENSIONAHA.118.11155. Epub 2018 May 7. No abstract available.

18.

Fluid retention, aldosterone excess, and treatment of resistant hypertension.

Calhoun DA.

Lancet Diabetes Endocrinol. 2018 Jun;6(6):431-433. doi: 10.1016/S2213-8587(18)30080-9. Epub 2018 Apr 11. No abstract available.

19.

Role of Mineralocorticoid Receptors in Obstructive Sleep Apnea and Metabolic Syndrome.

Valaiyapathi B, Calhoun DA.

Curr Hypertens Rep. 2018 Mar 19;20(3):23. doi: 10.1007/s11906-018-0819-5. Review.

PMID:
29556729
20.

Medical Versus Surgical Treatment of Primary Aldosteronism.

Calhoun DA.

Hypertension. 2018 Apr;71(4):566-568. doi: 10.1161/HYPERTENSIONAHA.118.10759. Epub 2018 Feb 26. No abstract available.

21.

The association of nocturnal hypertension and nondipping blood pressure with treatment-resistant hypertension: The Jackson Heart Study.

Irvin MR, Booth JN 3rd, Sims M, Bress AP, Abdalla M, Shimbo D, Calhoun DA, Muntner P.

J Clin Hypertens (Greenwich). 2018 Mar;20(3):438-446. doi: 10.1111/jch.13199. Epub 2018 Feb 13.

22.

Prevalence and Clinical Characteristics of Refractory Hypertension.

Armario P, Calhoun DA, Oliveras A, Blanch P, Vinyoles E, Banegas JR, Gorostidi M, Segura J, Ruilope LM, Dudenbostel T, de la Sierra A.

J Am Heart Assoc. 2017 Dec 7;6(12). pii: e007365. doi: 10.1161/JAHA.117.007365.

23.

Antihypertensive Medications and Falls in the Elderly.

Cai A, Calhoun DA.

Am J Hypertens. 2018 Feb 9;31(3):281-283. doi: 10.1093/ajh/hpx203. No abstract available. Erratum in: Am J Hypertens. 2018 Mar 10;31(4):513.

PMID:
29186306
24.

True versus pseudoresistant hypertension.

Calhoun DA, Grassi G.

J Hypertens. 2017 Dec;35(12):2367-2368. doi: 10.1097/HJH.0000000000001568. No abstract available.

PMID:
29095227
25.

Refractory versus resistant hypertension: Novel distinctive phenotypes.

Dudenbostel T, Siddiqui M, Gharpure N, Calhoun DA.

J Nat Sci. 2017 Sep;3(9). pii: e430.

26.

Maternal and neonatal demographics of macrosomic infants admitted to the neonatal intensive care unit.

Tolosa JN, Calhoun DA.

J Perinatol. 2017 Dec;37(12):1292-1296. doi: 10.1038/jp.2017.128. Epub 2017 Aug 24.

PMID:
28837137
27.

White-Coat Effect Is Uncommon in Patients With Refractory Hypertension.

Siddiqui M, Judd EK, Oparil S, Calhoun DA.

Hypertension. 2017 Sep;70(3):645-651. doi: 10.1161/HYPERTENSIONAHA.117.09464. Epub 2017 Jul 10.

28.

Glomerular Hyperfiltration in Obese African American Hypertensive Patients Is Associated With Elevated Urinary Mitochondrial-DNA Copy Number.

Eirin A, Saad A, Woollard JR, Juncos LA, Calhoun DA, Tang H, Lerman A, Textor SC, Lerman LO.

Am J Hypertens. 2017 Nov 1;30(11):1112-1119. doi: 10.1093/ajh/hpx103. Erratum in: Am J Hypertens. 2017 Nov 1;30(11):1145.

29.

Resistant Hypertension: An Update of Experimental and Clinical Findings.

Cai A, Calhoun DA.

Hypertension. 2017 Jul;70(1):5-9. doi: 10.1161/HYPERTENSIONAHA.117.08929. Epub 2017 May 15. Review. No abstract available.

30.

Sleep disorders and hypertension risk.

Calhoun DA.

J Hum Hypertens. 2017 Jun;31(6):371-372. doi: 10.1038/jhh.2017.2. No abstract available.

PMID:
28465616
31.

National patterns in intensity and frequency of outpatient care for apparent treatment-resistant hypertension.

Vemulapalli S, Deng L, Patel MR, Kilgore ML, Jones WS, Curtis LH, Irvin MR, Svetkey LP, Shimbo D, Calhoun DA, Muntner P.

Am Heart J. 2017 Apr;186:29-39. doi: 10.1016/j.ahj.2017.01.008. Epub 2017 Jan 19.

PMID:
28454830
32.

Distinctive Risk Factors and Phenotype of Younger Patients With Resistant Hypertension: Age Is Relevant.

Ghazi L, Oparil S, Calhoun DA, Lin CP, Dudenbostel T.

Hypertension. 2017 May;69(5):827-835. doi: 10.1161/HYPERTENSIONAHA.116.08632. Epub 2017 Mar 27.

33.

11-Beta Dehydrogenase Type 2 Activity Is Not Reduced in Treatment Resistant Hypertension.

Ghazi L, Dudenbostel T, Hachem ME, Siddiqui M, Lin CP, Oparil S, Calhoun DA.

Am J Hypertens. 2017 May 1;30(5):518-523. doi: 10.1093/ajh/hpx002.

34.

Assessment of vascular function in low socioeconomic status preschool children: a pilot study.

Ghazi L, Dudenbostel T, Xing D, Ejem D, Turner-Henson A, Joiner CI, Affuso O, Azuero A, Oparil S, Calhoun DA, Rice M, Hage FG.

J Am Soc Hypertens. 2017 Feb;11(2):101-109. doi: 10.1016/j.jash.2016.12.006. Epub 2016 Dec 24.

35.

Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT.

Bangalore S, Davis BR, Cushman WC, Pressel SL, Muntner PM, Calhoun DA, Kostis JB, Whelton PK, Probstfield JL, Rahman M, Black HR; ALLHAT Collaborative Research Group.

Am J Med. 2017 Apr;130(4):439-448.e9. doi: 10.1016/j.amjmed.2016.10.002. Epub 2016 Oct 27.

36.

Update From the Editors to Our Readers.

Schiffrin EL, Calhoun DA, Flack JM, Ito S, Webb RC.

Am J Hypertens. 2017 Jan;30(1):1-2. No abstract available.

PMID:
27940428
37.

Effects of Spironolactone and Renal Denervation Treatment on Blood Pressure and Its Variability-Different Aspects of Hypertension Treatment.

Dudenbostel T, Calhoun DA.

Am J Hypertens. 2017 Jan;30(1):12-15. Epub 2016 Nov 12. No abstract available.

PMID:
27838625
38.

Refractory versus resistant hypertension.

Siddiqui M, Calhoun DA.

Curr Opin Nephrol Hypertens. 2017 Jan;26(1):14-19. Review.

PMID:
27798457
39.

Refractory and Resistant Hypertension: Antihypertensive Treatment Failure versus Treatment Resistance.

Calhoun DA.

Korean Circ J. 2016 Sep;46(5):593-600. Epub 2016 Sep 28. Review.

40.

Sympathetic Activity, Hypertension, and The Importance of a Good Night's Sleep.

Biaggioni I, Calhoun DA.

Hypertension. 2016 Dec;68(6):1338-1339. Epub 2016 Oct 3. No abstract available.

41.

Use of Aldosterone Antagonists for Treatment of Uncontrolled Resistant Hypertension.

Dudenbostel T, Calhoun DA.

Am J Hypertens. 2017 Feb;30(2):103-109. doi: 10.1093/ajh/hpw105. Epub 2016 Sep 8. Review.

42.

The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationale.

Saddekni MB, Saag KG, Dudenbostel T, Oparil S, Calhoun DA, Sattui SE, Feig DI, Muntner P, Redden DT, Foster PJ, Rahn EJ, Biggers SR, Li P, Gaffo AL.

Contemp Clin Trials. 2016 Sep;50:238-44. doi: 10.1016/j.cct.2016.08.016. Epub 2016 Aug 30.

43.

Renal Nerve Denervation, Adherence, and Management of Resistant Hypertension.

Calhoun DA.

Circulation. 2016 Sep 20;134(12):858-60. doi: 10.1161/CIRCULATIONAHA.116.024385. Epub 2016 Aug 30. No abstract available.

PMID:
27576779
44.

Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension.

Dudenbostel T, Ghazi L, Liu M, Li P, Oparil S, Calhoun DA.

Hypertension. 2016 Oct;68(4):995-1003. doi: 10.1161/HYPERTENSIONAHA.116.07806. Epub 2016 Aug 15.

45.

Spironolactone versus renal nerve denervation for treatment of uncontrolled resistant hypertension.

Calhoun DA.

J Hypertens. 2016 Sep;34(9):1701-3. doi: 10.1097/HJH.0000000000001033. No abstract available.

PMID:
27488549
46.

Comparisons of sleep apnoea rate and outcomes among patients with resistant and non-resistant hypertension.

Bhandari SK, Shi J, Molnar MZ, Rasgon SA, Derose SF, Kovesdy CP, Calhoun DA, Kalantar-Zadeh K, Jacobsen SJ, Sim JJ.

Respirology. 2016 Nov;21(8):1486-1492. doi: 10.1111/resp.12840. Epub 2016 Jul 18.

PMID:
27427469
47.

Do We Need a New Definition of Hypertension After SPRINT?

Schiffrin EL, Calhoun DA, Flack JM.

Am J Hypertens. 2016 Oct;29(10):1127-9. doi: 10.1093/ajh/hpw068. Epub 2016 Jun 22. No abstract available.

PMID:
27334926
48.

A practical approach for measurement of antihypertensive medication adherence in patients with resistant hypertension.

CorrĂȘa NB, de Faria AP, Ritter AM, Sabbatini AR, Almeida A, Brunelli V, Calhoun DA, Moreno H, Modolo R.

J Am Soc Hypertens. 2016 Jun;10(6):510-516.e1. doi: 10.1016/j.jash.2016.03.194. Epub 2016 Apr 5.

PMID:
27161936
49.

Refractory Hypertension: A Novel Phenotype of Antihypertensive Treatment Failure.

Dudenbostel T, Siddiqui M, Oparil S, Calhoun DA.

Hypertension. 2016 Jun;67(6):1085-92. doi: 10.1161/HYPERTENSIONAHA.116.06587. Epub 2016 Apr 18. Review. No abstract available.

50.

Drug Development for Hypertension: Do We Need Another Antihypertensive Agent for Resistant Hypertension?

Pimenta E, Calhoun DA.

Curr Hypertens Rep. 2016 Apr;18(4):25. doi: 10.1007/s11906-016-0634-9. Review.

PMID:
26949263

Supplemental Content

Loading ...
Support Center